Detalhe da pesquisa
1.
Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.
Biol Blood Marrow Transplant
; 25(5): 855-860, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30615982
2.
Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease.
Biol Blood Marrow Transplant
; 24(8): 1759-1765, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29656137
3.
T Cell-Mediated Rejection of Human CD34+ Cells Is Prevented by Costimulatory Blockade in a Xenograft Model.
Biol Blood Marrow Transplant
; 23(12): 2048-2056, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28818684
4.
Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease.
Biol Blood Marrow Transplant
; 22(3): 441-8, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26348889
5.
Renal dysfunction within 90 days of FluBu4 predicts early and late mortality.
Bone Marrow Transplant
; 54(7): 980-986, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30604772
6.
A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma.
Leuk Lymphoma
; 59(7): 1666-1671, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29065747